alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of CHDT Corporation on Form 10-Q for the period ended June 30, 2009, filed with the Securities and Exchange Commission (the “Report”), I, Gerry McClinton, Chief Operating Officer of the Company of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, hereby certify that:





(1)           the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)           the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.








/s/ Gerry McClinton


Gerry McClinton


Chief Operating Officer, Director


(Principal Operations Executive)








August 14, 2009








A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
#### Paul Andrew LEITNER-WISE, Plaintiff-Appellant v. LWRC INTERNATIONAL, LLC, Sig Sauer Inc., Defendants-Appellees

2017-1852

United States Court of Appeals, Federal Circuit.

February 12, 2018

Matthew August LeFande,- Matthew August LeFande Attorney at Law PLLC, Arlington, VA, argued for plaintiff-appellant.

Noam Barak Fischman, Polsinelli PC, Washington, DC, argued for defendant-appellee LWRC International, LLC. Also represented by Daniel Joseph Donohue,

Laura Carroll, Burns *&*Levinson, LLP, Boston, MA, argued for defendant-appellee Sig Sauer Inc. Also represented by Eric G.J. Kaviar.

(Prost, Chief Judge, Moore and Chen, Circuit Judges).

JUDGMENT

Per Curiam

This Cause having been heard and considered, it is Ordered and Adjudged:

AFFIRMED. *See*Fed. Cir. R. 36.
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Revolution Medicines, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

|   | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

 

| Date: March 30, 2020 | By:    | /s/ Mark A. Goldsmith                                  |
|----------------------|--------|--------------------------------------------------------|
|                 |   | Mark A. Goldsmith, M.D., Ph.D.                         |
|                 |   | Chief Executive Officer

(Principal Executive Officer) |
### THE THIRTEENTH COURT OF APPEALS

13

- 23

- 00251

- CR

Jason Dale January v. The State of Texas

On Appeal from the 24th District Court of Calhoun County , Texas

Trial Court Cause No. 2022

- CR

- 8645

- DC

JUDGMENT THE THIRTEENTH COURT OF APPEALS, having consider ed this cause on appeal, concludes that the judgment of the trial court should be affirmed as modified by
this Court . The Court orders the judgment of the trial court AFFIRMED AS MODIFIED

. We further order this decision certified below for observance. Apr il 4, 2024
<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (date of earliest event reported): April 16, 2003

                             Equistar Chemicals, LP
             (Exact name of registrant as specified in its charter)

            Delaware                  333-76473                  76-0550481
(State or other jurisdiction of      (Commission              (I.R.S. Employer
       incorporation)                File Number)            Identification No.)

                              1221 McKinney Street
                         Suite 700, Houston, Texas 77010
              (Address of principal executive offices and zip code)

        Registrant's telephone number, including area code: 713-652-7200

<PAGE>


Item 5. Other Events.

On April 16, 2003 Equistar Chemicals, LP ("Equistar") announced that it will
sell $450 million of 10-5/8% senior notes at par in a private placement offering
announced earlier this week. The notes will mature May 1, 2011. Equistar's April
16, 2003 press release regarding the offering is being filed with this Current
Report on Form 8-K as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

        (c) Exhibits.

            99.1     Press Release

<PAGE>


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                             Equistar Chemicals, LP

                             By: /s/ Gerald A. O'Brien
                                 -----------------------------------------------
                                Gerald A. O'Brien
                                Vice President, General Counsel and Secretary

Date:    April 16, 2003

<PAGE>


                                INDEX TO EXHIBITS

Exhibit
Number            Description
-------           -----------
99.1              Press Release
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 07-6650

ODELL REED, JR., Plaintiff - Appellant, versus JULIA LAFOON, Nurse at Brunswick Correctional Center; she is sued in her individual and official capacity; ALVIN E. HARRIS, Doctor at Brunswick Correctional Center; he is sued in his individual and official capacity; K. RUNION, Warden at Brunswick Correctional Center; he is sued in his individual and official capacity; FRED SCHILLING, Health Service Director for Virginia Department of Corrections; he is sued in his individual and official capacity; GENE M. JOHNSON, Director for the Virginia Department of Corrections; he is sued in his individual and official capacity, Defendants - Appellees. Appeal from the United States District Court for the Eastern District of Virginia, at Alexandria. Claude M. Hilton, Senior District Judge. (1:07-cv-00186-CMH) Submitted: October 31, 2007 Decided: November 13, 2007 Before WILKINSON, TRAXLER, and SHEDD, Circuit Judges. Affirmed by unpublished per curiam opinion.- 2 - Odell Reed, Jr., Appellant Pro Se. Unpublished opinions are not binding precedent in this circuit.- 3 - PER CURIAM: Odell Reed, Jr., appeals the district court’s order dismissing his 42 U.S.C. § 1983 (2000) action under 28 U.S.C. § 1915A(b) (2000), for failure to state a claim upon which relief may be granted. We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. Reed v. Lafoon , No. 1:07-cv-00186-CMH (E.D. Va. filed Mar. 28, 2007 & entered Apr. 2, 2007). We deny Reed’s motion to submit new evidence and dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
An official website of the United States government         Here's how you know         
**Official websites use .mil**
A **.mil** website belongs to an official U.S. Department of Defense organization in the United States.
**Secure .mil websites use HTTPS**
 A **lock (lock )** or **https://** means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

Skip to main content (Press Enter).

Defense Threat Reduction Agency 

Search
Search

Search

-  Home		 
-  About    -  DTRA Leadership             
  -  DTRA History             
  -  Mission             
  -  Strategic Initiatives             
  -  Foreign Malign Influence             
  -  Agency Overview Brief (pdf)             
  -  Agency Financial Report 
-  Careers & Opportunities    -  Your Civilian Career             
  -  Your Military Career             
  -  Welcome Aboard 
-  Business    -  DTRA Contract Award Data             
  -  Office of Small Business             
  -  Mentor Protege Program 
-  News & Media    -  Press Center 
-  Contact Us		 
-  Joint Operations Center		 

# DTRA FOIA Reading Room Archive

                            -  1 
                            -  2 

FOIA Request 21-042

FOIA Request 20-063 First Interim

FOIA Request 20-063 Second Interim

FOIA Request 20-063 Third Interim

FOIA Request 20-063 Fourth Interim

FOIA Request 20-063 Fifth Interim

FOIA Request 20-063 Final Response 

FOIA Request 22-006

FOIA Request 21-005

FOIA Request 21-006

                            -  1 
                            -  2 

### Stay Connected

Hosted by Defense Media Activity - WEB.mil
COURT OF APPEALS FOR THE

FIRST DISTRICT OF TEXAS AT HOUSTON

ORDER ON MOTION

Cause Number: 01-13-00102-CV

Trial Court Cause 

Number: 907501

Style: Svetlana B. Poplin

v Amerisure Insurance Company

Date motion filed*: November 11, 2014

Type of motion: Motion for Rehearing

Party filing motion: Appellant

Document to be filed: no

Is appeal accelerated? YES NO

Ordered that motion is:

 Granted

If document is to be filed, document due: 

Absent extraordinary circumstances, the Court will not grant additional motions to extend time

 Denied

 Dismissed (e.g., want of jurisdiction, moot)

 Other: 

Judge's signature: /s/ Sherry Radack 

 Acting individually Acting for the Court

Panel consists of Chief Justice Radack, and Justices Bland and Huddle 

Date: January 14, 2014
H. J. Res. 137

One Hundred Fifth Congress

of the

United States of America

AT THE SECOND SESSION

Begun and held at the City of Washington on Tuesday,

the twenty-seventh day of January, one thousand nine hundred and ninety-eight

Joint Resolution

Making further continuing appropriations for the fiscal year 1999, and for other

purposes.

Resolved by the Senate and House of Representatives of the

United States of America in Congress assembled, That section 106(c)

of Public Law 105–240 is further amended by striking ‘‘October

20, 1998’’ and inserting in lieu thereof ‘‘October 21, 1998’’.

Speaker of the House of Representatives.

Vice President of the United States and

President of the Senate.
No. 11-1516.

#### Kim et al. *v.*Village at Eagle Creek Homeowners Assn. et al.

Ct. App. Ind. Certiorari denied.
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-15-00637-CV

Airlinx Communications, Inc., Appellant

v.

Ultra Electronics Advanced Tactical Systems, Inc., Appellee

FROM THE DISTRICT COURT OF TRAVIS COUNTY, 353RD JUDICIAL DISTRICT

NO. D-1-GN-12-002873, HONORABLE AMY CLARK MEACHUM, JUDGE PRESIDING

M E M O R A N D U M O P I N I O N

Appellant Airlinx Communications, Inc. seeks to appeal a final judgment signed

on July 15, 2015. According to the clerk’s record, no motion for new trial or other post-judgment

motion was filed. See Tex. R. App. P 26.1(a) (when certain post-judgment motions are filed, notice

of appeal is due within ninety days after judgment is signed). Consequently, Airlinx’s deadline to

file its notice of appeal was August 14, 2015. See id. R. 26.1 (generally, notice of appeal must be

filed within thirty days after judgment is signed). Airlinx’s notice of appeal was not filed until

October 7, 2015.

The Clerk of this Court notified Airlinx, by letter, that it appeared that Airlinx’s

notice of appeal was not timely filed and, as a result, that the Court lacked jurisdiction to consider

this appeal. Airlinx responded in writing, asserting that its notice of appeal should be deemed timely

under the mailbox rule, Rule 9.2 of the Texas Rules of Appellate Procedure. See id. R. 9.2. In support
of its assertion, Airlinx submitted the affidavit of its President, Tjalling Hoiska, stating that “the

notice of appeal for this trial court case was mailed to the district clerk’s office on or before

August 14, 2015.”

A document is deemed timely filed under mailbox rule only when (1) the document

is properly deposited in the mail or delivered to a commercial delivery service on or before the last

day for filing and (2) the document is received by the clerk within ten days of the filing deadline.

See id. R. 9.2(b). Here, Airlinx’s notice of appeal was file stamped by the trial court clerk on

October 7, 2015, and the signature block on the notice of appeal bears Hoiska’s signature and

purports to be signed by him on October 7, 2015. Based on the record before us, we have no basis

to conclude that Airlinx’s notice of appeal was received by the trial court within ten days after

the filing deadline, but not filed by the trial court clerk until October 7, 2015. Because Airlinx’s

notice of appeal was not timely filed and the mailbox rule does not apply, this Court lacks

jurisdiction to consider this appeal. See id. R. 25.1(b). We dismissthe appeal for want of jurisdiction.

See id. R. 42.3(a).

__________________________________________

Scott K. Field, Justice

Before Chief Justice Rose, Justices Pemberton and Field

Dismissed for Want of Jurisdiction

Filed: December 11, 2015

2
<PAGE>

                                                                    EXHIBIT 23.4

                       Consent of Independent Accountants

     We hereby consent to the incorporation by reference in this Amendment No. 5
to Registration Statement on Form S-4 of our report dated September 7, 2001
relating to the combined financial statements of the Gas Compression Business of
Schlumberger Limited, which appears in the Current Report on Form 8-K/A of
Hanover Compressor Company dated November 9, 2001. We also consent to the
reference to us under the heading "Experts" in such Registration Statement.

/s/ PricewaterhouseCoopers LLP


Houston, Texas
February 7, 2003
Exhibit
31.2



FORM
OF CERTIFICATION

PURSUANT
TO RULE 13a-14 AND 15d-14

UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

CERTIFICATIONS



I,
Shamyl Malik, certify that:



1.
I have reviewed this Amendment No. 1 to the annual report on Form 10-K of Long Blockchain Corp.;



2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report.



|Date:
    April 30, 2018 | /s/
    Shamyl Malik                                                                                                                 
|------------------------ | -------------------------------------------------------------------------------------------------------------------------------------
|                         | Shamyl
    Malik                                                                                                                     
|                         | Director
    and Chief Executive Officer  (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                          62,250
<SECURITIES>                                         0
<RECEIVABLES>                               22,399,605
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            22,842,429
<PP&E>                                      64,584,969
<DEPRECIATION>                               5,243,952
<TOTAL-ASSETS>                              91,338,253
<CURRENT-LIABILITIES>                       17,022,638
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    70,616,609
<OTHER-SE>                                (32,722,716)
<TOTAL-LIABILITY-AND-EQUITY>                91,338,253
<SALES>                                     16,984,741
<TOTAL-REVENUES>                            16,984,741
<CGS>                                       29,109,451
<TOTAL-COSTS>                               29,109,451
<OTHER-EXPENSES>                             4,100,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           4,115,036
<INCOME-PRETAX>                           (14,632,572)
<INCOME-TAX>                                   197,009
<INCOME-CONTINUING>                       (13,822,760)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (13,822,760)
<EPS-PRIMARY>                                    (.86)
<EPS-DILUTED>                                        0
        

</TABLE>
**Exhibit 32.2**
Certification pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     In connection with the Form 10-Q of Noven Pharmaceuticals, Inc. (“Noven”) for the three monthsended March 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the“Report”), I, Diane M. Barrett, Vice President and Chief Financial Officer of Noven, certify,pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that:
1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934, as amended; and
2) the information contained in the Report fairly presents, in all material respects, the financialcondition and results of operations of Noven.   /s/ Diane M. Barrett  Name: Diane M. Barrett  Title: Vice President and Chief Financial Officer  Date: May 4, 2005  
A signed original of this written statement required by Section 906 has been provided to NovenPharmaceuticals, Inc. and will be retained by Noven Pharmaceuticals, Inc. and furnished to theSecurities and Exchange Commission or its staff upon request.
IV

105TH CONGRESS

1ST SESSION H. CON. RES. 87

Providing for an adjournment of the two Houses.

IN THE HOUSE OF REPRESENTATIVES

MAY 22, 1997

Mr. ARMEY submitted the following concurrent resolution; which was

considered and failed passage

CONCURRENT RESOLUTION

Providing for an adjournment of the two Houses.

1 Resolved by the House of Representatives (the Senate

2 concurring), That when the House adjourns on the legisla3 tive day of Thursday, May 22, 1997, or Friday, May 23,

4 1997, pursuant to a motion made by the majority leader

5 or his designee, it stand adjourned until 12:30 p.m. on

6 Tuesday, June 3, 1997, or until noon on the second day

7 after Members are notified to reassemble pursuant to sec8 tion 2 of this concurrent resolution, whichever occurs first;

9 and that when the Senate recesses or adjourns at the close

10 of business on Thursday, May 22, 1997, Friday, May 23,

11 1997, or Saturday, May 24, 1997, pursuant to a motion

12 made by the majority leader, or his designee, in accord-
2

HCON 87 IH

1 ance with this concurrent resolution, it stand recessed or

2 adjourned until noon on Monday, June 2, 1997, or such

3 time on that day as may be specified by the majority lead4 er or his designee in the motion to recess or adjourn, or

5 until noon on the second day after Members are notified

6 to reassemble pursuant to section 2 of this concurrent res7 olution, whichever occurs first.

8 SEC. 2. The Speaker of the House and the majority

9 leader of the Senate, acting jointly after consultation with

10 the minority leader of the House and the minority leader

11 of the Senate, shall notify the Members of the House and

12 the Senate, respectively, to reassemble whenever, in their

13 opinion, the public interest shall warrant it.

Æ
No. 11-9395.

#### Cleaver-Bascombe *v.*Kartano.

Ct. App. D. C. Certiorari denied.
Exhibit








Exhibit 10.2


CLECO CORPORATE HOLDINGS LLC 
Supplemental Executive Retirement Plan 
Amended and Restated Effective January 1, 2009 
Amendment No. 4
(Special CEO Benefit)
Whereas, Cleco Corporation (the "Company") maintains the Supplemental Executive Retirement Plan, most recently amended and restated effective as of January 1, 2009, and most recently amended effective July 24, 2014, which plan is intended to be a non-qualified deferred compensation arrangement structured in the form of a defined benefit plan (the "SERP");
Whereas, the Board of Directors of the Company now desires to limit participation in the SERP;
Now, Therefore, Be It Resolved, that a Special CEO Benefit shall be added to the SERP, effective January 1, 2018; as shown on Exhibit A hereto; and
Further Resolved, that the SVP - General Counsel & Director - Regulatory Compliance, is hereby authorized, empowered and directed to take any and all actions which she, in her sole discretion, shall deem necessary or advisable in order to accomplish the forgoing resolution.
.This Amendment No. 4 was approved by the Board of Directors of Cleco Corporation on December 14, 2017, to be effective as of the date set forth herein.
Cleco Corporate Holdings LLC
By: /s/ Anthony Bunting                                                     Anthony Bunting
Date: December 21, 2017













EXHIBIT A




Article V of the Plan shall be amended by inserting a new Section 5.6, to read, in its entirety, as 
follows:


5.6   Special CEO Benefit.  Notwithstanding anything herein to the contrary, including Section 
5.3, except that the Benefit Offsets provision of Section 5.3 shall continue to apply, and Section 
5.4, the annual amount of payment for William G. Fontenot shall be determined pursuant to the 
following, depending upon the year of the Separation Date:






	
		
	Year
	Annual 
Benefit

	2018
	$199,440

	2019
	$220,000

	2020
	$240,000

	2021
	$265,000

	2022
	$295,000

	2023
	$330,000

	2024
	$365,000

	2025
	$400,000

	2026
	$408,000

	2027
	$416,160

	2028
	$424,483








In the event the Separation Date is in 2029 or later, the 2028 annual payment shall be increased 
by 2% for each such year.




CLECO CORPORATE HOLDINGS LLC
/s/ Anthony Bunting                    
Name:  Anthony Bunting
Date:    12/21/17